Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 2/2012

Open Access 01-04-2012 | Open Access: Current Opinion

Clinical Relevance of Botulinum Toxin Immunogenicity

Author: Professor Reiner Benecke

Published in: BioDrugs | Issue 2/2012

Login to get access

Abstract

Botulinum toxin type A is a 150 kD protein produced by Clostridium botulinum, which exists in a complex with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the neuromuscular junction has been exploited for use in medical conditions characterized by muscle hyperactivity. As such, botulinum toxin is widely recommended by international treatment guidelines for movement disorders and it has a plethora of other clinical and cosmetic indications. The chronic nature of these conditions requires repeated injections of botulinum toxin, usually every few months. Multiple injections can lead to secondary treatment failure in some patients that may be associated with the production of neutralizing antibodies directed specifically against the neurotoxin. However, the presence of such antibodies does not always render patients non-responsive. The reported prevalence of immunoresistance varies greatly, depending on factors such as study design and treated indication. This review presents what is currently known about the immunogenicity of botulinum toxin and how this impacts upon patient non-response to treatment. The complexing proteins may act as adjuvants and stimulate the immune response. Their role and that of neutralizing and non-neutralizing antibodies in the response to botulinum toxin is discussed, together with an assessment of current neutralizing antibody measurement techniques. Botulinum toxin preparations with different compositions and excipients have been developed. The major commercially available preparations of botulinum toxin are Botox® (onabotulinumtoxinA; Allergan, Inc., Ireland), Dysport® (abobotulinumtoxinA; Ipsen Ltd, UK), and Xeomin® (incobotulinumtoxinA; botulinum toxin type A [150 kD], free from complexing proteins; NT 201; Merz Pharmaceuticals GmbH, Germany). The new preparations of botulinum toxin aim to minimize the risk of immunoresistance in patients being treated for chronic clinical conditions.
Literature
1.
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21–5PubMed
2.
Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur JNeurol 2011; 18: 5–18PubMedCrossRef
3.
Novak I, Campbell L, Boyce M, et al. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 2010; 17 Suppl. 2: 94–108PubMedCrossRef
4.
Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699–706PubMedCrossRef
5.
Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1691–8PubMedCrossRef
6.
Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19Suppl. 8: S92–100PubMedCrossRef
7.
8.
Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 2005; 1050: 257–65PubMedCrossRef
9.
Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48: 26–9PubMedCrossRef
10.
Sharma SK, Fu FN, Singh BR. Molecular properties of a hemagglutinin purified from type A Clostridium botulinum. J Protein Chem 1999; 18: 29–38PubMedCrossRef
11.
Eisele KH, Fink K, Vey M, et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57: 555–65PubMedCrossRef
12.
Lee J-C, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2005; 151: 3739–47PubMedCrossRef
13.
Kukreja R, Chang T-W, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 2009; 53: 616–24PubMedCrossRef
14.
Atassi MZ. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2006; 152: 1891–5PubMedCrossRef
15.
Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/ Azzalure®, and Xeomin®/Bocouture®. Drugs R D 2010; 10: 67–73PubMedCrossRef
16.
Sun Y, Wang L, Singh BR. Botulinum neurotoxin type A complex proteins bind to neuronal as well as non-neuronal cells [poster]. 14th International Congress of Parkinson’s Disease and Movement Disorders; 2010 Jun 13–17; Buenos Aires, Argentina
17.
Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004; 19Suppl. 8: S68–84PubMedCrossRef
18.
Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431–8PubMedCrossRef
19.
Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003; 250: 967–9PubMedCrossRef
20.
21.
Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006; 13Suppl. 1: 11–5PubMedCrossRef
22.
Kamm C, Benecke R. Individualized management of cervical dystonia with different serotypes of botulinum toxin: recent therapeutic advances and risk development of neutralizing antibodies. Eur Neurol J 2010; 2: 49–54
23.
Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46: 26–9PubMedCrossRef
24.
Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies — therapeutic consequences. Exp Neurol 1997; 147: 96–102PubMedCrossRef
25.
Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 2004; 61Suppl. 6: S5–10PubMed
26.
Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186–8PubMedCrossRef
27.
Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20: 592–7PubMedCrossRef
28.
Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J, Albanese A, Atassi MZ, et al., editors. Botulinum toxin: therapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier, 2009: 389–97CrossRef
29.
30.
31.
Eisele KH, Taylor HV, Bluemel lJ. Immunogenicity of NT 201 (Xeomin®) in Cynomolgus monkeys following repeated, high dose injections [poster]. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC) Meeting; 2007 Oct 14–18; Asilomar (CA)
32.
Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 2007; 67: 669–83PubMedCrossRef
33.
Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010; 4: 325–32PubMed
34.
35.
Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008; 23: 1353–60PubMedCrossRef
36.
Minnasch P. Presence of neutralising antibodies in a patient population with cervical dystonia prior to clinical study entry [poster]. American Academy of Neurology Annual Meeting; 2010 Apr 10–17; Honolulu (HI)
37.
Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009; 31: 463–6PubMedCrossRef
38.
Müller K, Mix E, Adib Saberi F, et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 2009; 116: 579–85PubMedCrossRef
39.
Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25: 2211–8PubMedCrossRef
40.
Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16: 316–23PubMedCrossRef
41.
Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213–7PubMedCrossRef
42.
Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55: 732–5PubMedCrossRef
43.
Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuro-muscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108: 1062–71PubMedCrossRef
44.
European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins [online]. Available from URL: www.ema.europa.eu/pdfs/human/biosimilar/1432706en.pdf USL} [Accessed 2011 Jan 26]
45.
Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008; 15: 407–15PubMedCrossRef
46.
Kranz G, Sycha T, Voller B, et al. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology 2008; 70: 133–6PubMedCrossRef
47.
Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009; 32: 213–8PubMedCrossRef
48.
Shone C, Wilton-Smith P, Appleton N, et al. Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 1985; 50: 63–7PubMed
49.
Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 2001; 45: 257–60PubMedCrossRef
50.
Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999; 66: 612–6PubMedCrossRef
51.
Palace J, Nairne A, Hyman N, et al. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology 1998; 50: 1463–6PubMedCrossRef
52.
Dressler D, Lange M, Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 2005; 20: 1617–9PubMedCrossRef
53.
Rasetti-Escargueil C, Lui Y, Rigsby P, et al. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 2011; 57: 1008–16PubMedCrossRef
54.
Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York (NY): Marcel Dekker, 1994: 93–107
55.
Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994; 17: 1385–92PubMedCrossRef
56.
Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 2000; 247: 630–2PubMedCrossRef
57.
Birklein F, Erbguth F. Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A: a preliminary observation. Mov Disord 2000; 15: 146–9PubMedCrossRef
58.
Botox®: US prescribing information. Irvine (CA): Allergan, Inc., 2010
59.
Dysport®: US prescribing information. Wrexham: Ipsen Biopharm, Ltd., 2010
60.
BTXA®: Prescribing information. Gansu: Lanzhou Institute of Biological Products, 2011
61.
62.
63.
Myobloc®: US prescribing information. San Francisco (CA): Solstice Neurosciences, Inc., 2009
64.
Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459–62PubMed
65.
Chadda S, Tilden D, Jones D, et al. Cost effectiveness of Xeomin® in the management of cervical dystonia and blepharospasm. Eur J Hosp Pharm 2009; 15: 38–46
66.
Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005; 20: 937–44PubMedCrossRef
67.
Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949–51PubMedCrossRef
68.
Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303–12PubMedCrossRef
69.
Wohlfarth K, Müller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 2007; 30: 86–94PubMedCrossRef
70.
Sesardic D. Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? Drugs R D 2010; 10: 91–2PubMedCrossRef
71.
Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D 2011; 11: 97–8PubMedCrossRef
72.
Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36 Suppl. 4: 2146–54PubMedCrossRef
Metadata
Title
Clinical Relevance of Botulinum Toxin Immunogenicity
Author
Professor Reiner Benecke
Publication date
01-04-2012
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 2/2012
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/11599840-000000000-00000

Other articles of this Issue 2/2012

BioDrugs 2/2012 Go to the issue

Adis Profile Report

DTaP5-IPV-Hib Vaccine (Pediacel®)

Systematic Review

Hyaluronic Acid for the Treatment of Osteoarthritis in all Joints Except the Knee

Adis Drug Clinical Q&A

Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria

Review Article

Rituximab

Short Communication

How Much are Biosimilars Used in Southern Italy?

Current Opinion

Biologic Rheumatoid Arthritis Therapies